Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 act mut |
| Therapy | Ivosidenib |
| Indication/Tumor Type | malignant astrocytoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 act mut | malignant astrocytoma | sensitive | Ivosidenib | Guideline | Actionable | Tibsovo (ivosidenib) is included in guidelines for patients with WHO grade 2 astrocytoma harboring an IDH1 activating mutation with residual/measurable disease or as adjuvant treatment after surgery/biopsy or recurrent or progressive disease and WHO grade 3 or 4 with recurrent or progressive disease or WHO grade 3 as adjuvant treatment (category 2B) (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |